A number of more knowledgeable contributors here have suggested MSB needs partners for drugs where the market is far greater than that for Ryoncil ie CHF, lower back pain. Is this partnership just for sales and distribution? Or is it manufacturing capacity or something else. Why is this so? Surely with such revolutionary drugs the market will come to us.
Grasshopper
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.64 |
Change
0.023(1.39%) |
Mkt cap ! $2.111B | |||
| Open | High | Low | Value | Volume |
| $1.64 | $1.67 | $1.63 | $2.687M | 1.630M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 53654 | $1.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.65 | 71003 | 21 |
View Market Depth
| Last trade - 14.23pm 27/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |